Product information and disease description Place of product in therapy Disease description Epidemiology

Prevalence of Neovascular age-related macular degeneration

9 evidence topics · 8 sources

United States: prevalence of early and late AMD in 2019

“For 2019, we estimated that there were 18.34 million people 40 years and older (95% uncertainty interval [UI], 15.30-22.03) living with early-stage AMD, corresponding to a crude prevalence rate of 11.64% (95% UI, 9.71-13.98). We estimated there were 1.49 million people 40 years and older (95% UI, 0.97-2.15) living with late-stage AMD, corresponding to a crude prevalence rate of 0.94% (95% UI, 0.62-1.36).” (opens the source at this quote in a new tab)
“Prevalence of late-stage AMD increased with age from 0.02% (95% UI, 0.01-0.05) among those 40 to 44 years (Figure 3) to 11.39% (95% UI, 6.45-18.46) among people 85 years or older.” (opens the source at this quote in a new tab)
“The gender- and age-standardized rate of late AMD for non-Hispanic White individuals 40 years and older was 1.03% (95% UI, 0.65-1.52).” (opens the source at this quote in a new tab)

United States: late AMD definition used in 2019 prevalence estimates

“late-stage (defined as choroidal neovascularization and/or geographic atrophy in either eye) manifestations of AMD.” (opens the source at this quote in a new tab)

United States: prevalence in 2000 and projection to 2020

“The overall prevalence of neovascular AMD and/or geographic atrophy in the US population 40 years and older is estimated to be 1.47% (95% confidence interval, 1.38%-1.55%), with 1.75 million citizens having AMD. The prevalence of AMD increased dramatically with age, with more than 15% of the white women older than 80 years having neovascular AMD and/or geographic atrophy.” (opens the source at this quote in a new tab)
“Owing to the rapidly aging population, the number of persons having AMD will increase by 50% to 2.95 million in 2020.” (opens the source at this quote in a new tab)

United States: NHANES 2005 to 2008

“In the civilian, noninstitutionalized, US population aged 40 years and older, the estimated prevalence of any AMD was 6.5% (95% confidence interval, 5.5-7.6) and the estimated prevalence of late AMD was 0.8% (95% confidence interval, 0.5-1.3).” (opens the source at this quote in a new tab)

United States: projection to 2050 and share of AMD that is neovascular

“Aging is the greatest risk factor; therefore, the prevalence of AMD in the United States is anticipated to increase to 22 million by the year 2050, whereas the global prevalence is expected to increase to 288 million by the year 2040.” (opens the source at this quote in a new tab)
“Although an estimated 80% of patients with age-related macular degeneration (AMD) have non-neovascular or atrophic AMD, the neovascular form is responsible for most of the severe vision loss associated with AMD.” (opens the source at this quote in a new tab)

Global: pooled prevalence and projections to 2040

“Analysis of 129,664 individuals (aged 30-97 years), with 12,727 cases from 39 studies, showed the pooled prevalence (mapped to an age range of 45-85 years) of early, late, and any age-related macular degeneration to be 8.01% (95% CrI 3.98-15.49), 0.37% (0.18-0.77), and 8.69% (4.26-17.40), respectively.” (opens the source at this quote in a new tab)
“The projected number of people with age-related macular degeneration in 2020 is 196 million (95% CrI 140-261), increasing to 288 million in 2040 (205-399).” (opens the source at this quote in a new tab)

Global: prevalence by ancestry

“The pooled prevalence of any AMD is approximately 8.69% (95% credible interval [CrI], 4.26-17.40) in persons aged 45 to 85 years, with a prevalence in people who are of European origin of 12.33% (95% CrI, 6.46-22.75), 10.43% (95% CrI, 5.27-20.01) in people who are of Hispanic origin, 7.53% (95% CrI, 3.80-14.89) in people who are of African origin, and 7.38% (95% CrI, 3.80-14.89) in people who are of Asian origin.” (opens the source at this quote in a new tab)

Europe: pooled prevalence in adults aged 60 years and older

“Our pooled prevalence estimate of early or intermediate AMD and any late AMD in those 60 years and older was 25.3% (95% CI 18.0% to 34.4%) and 2.4% (95% CI 1.8% to 3.3%), respectively.” (opens the source at this quote in a new tab)

Global: prevalence of vision impairment due to AMD, 1990 to 2021, with forecasts to 2050

“Globally, the number of individuals with vision impairment due to AMD more than doubled, rising from 3·64 million (95% uncertainty inverval [UI] 3·04-4·35) in 1990 to 8·06 million (6·71-9·82) in 2021.” (opens the source at this quote in a new tab)
“The burden of vision impairment due to AMD is projected to increase to about 21·34 million in 2050.” (opens the source at this quote in a new tab)